These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32452656)

  • 41. Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis.
    Lin X; Lin K; Lin C; Liu T; Ba M; Tang Y; Wang J; Zhou L; Wang J; Xiao C
    Int Immunopharmacol; 2021 Feb; 91():107280. PubMed ID: 33370681
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis.
    Naruse K; Yamada Y; Aoki S; Taki T; Nakamura K; Tobiume M; Zennami K; Katsuda R; Sai S; Nishio Y; Inoue Y; Noguchi H; Hondai N
    Hinyokika Kiyo; 2007 May; 53(5):287-92. PubMed ID: 17561711
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis.
    Li G; Wang Z; Xu J; Wu H; Cai S; He Y
    BMC Cancer; 2016 Mar; 16():249. PubMed ID: 27016045
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer.
    Akamatsu S; Kubota M; Uozumi R; Narita S; Takahashi M; Mitsuzuka K; Hatakeyama S; Sakurai T; Kawamura S; Ishidoya S; Hoshi S; Ishida M; Mizuno K; Ogura K; Goto T; Terada N; Kobayashi T; Yamasaki T; Inoue T; Tsuchiya N; Ohyama C; Arai Y; Habuchi T; Morita S; Ogawa O
    Eur Urol Oncol; 2019 May; 2(3):320-328. PubMed ID: 31200847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial.
    Tong T; Lei H; Guan Y; Yang X; Liao G; Li Y; Jiang D; Pang J
    Front Oncol; 2020; 10():586192. PubMed ID: 33330067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.
    Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM
    Ann Oncol; 2019 Aug; 30(8):1370-1380. PubMed ID: 31150059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer.
    Sun Y; Chen G; He J; Huang ZG; Li SH; Yang YP; Zhong LY; Ji SF; Huang Y; Chen XH; He ML; Wu H
    Bioengineered; 2021 Dec; 12(1):325-340. PubMed ID: 33356818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic value of pretreatment serum lactate dehydrogenase level in pancreatic cancer patients: A meta-analysis of 18 observational studies.
    Gan J; Wang W; Yang Z; Pan J; Zheng L; Yin L
    Medicine (Baltimore); 2018 Nov; 97(46):e13151. PubMed ID: 30431587
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.
    Petrelli F; Ardito R; Merelli B; Lonati V; Cabiddu M; Seghezzi S; Barni S; Ghidini A
    Melanoma Res; 2019 Feb; 29(1):1-12. PubMed ID: 30308577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shirotake S; Takamatsu K; Mizuno R; Kaneko GO; Nishimoto K; Oya M; Oyama M
    Anticancer Res; 2019 Aug; 39(8):4371-4377. PubMed ID: 31366532
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Size of pelvic bone metastasis as a significant prognostic factor for metastatic prostate cancer patients.
    Hayakawa T; Tabata KI; Tsumura H; Kawakami S; Katakura T; Hashimoto M; Watanabe Y; Iwamura M; Hasegawa T; Ishiyama H
    Jpn J Radiol; 2020 Oct; 38(10):993-996. PubMed ID: 32537698
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.
    Mori K; Kimura T; Onuma H; Kimura S; Yamamoto T; Sasaki H; Miki J; Miki K; Egawa S
    Prostate; 2017 Jul; 77(10):1144-1150. PubMed ID: 28557065
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Response Prediction of
    Rathke H; Holland-Letz T; Mier W; Flechsig P; Mavriopoulou E; Röhrich M; Kopka K; Hohenfellner M; Giesel FL; Haberkorn U; Kratochwil C
    J Nucl Med; 2020 May; 61(5):689-695. PubMed ID: 31653712
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The prognostic significance of Gleason scores in metastatic prostate cancer.
    Rusthoven CG; Carlson JA; Waxweiler TV; Yeh N; Raben D; Flaig TW; Kavanagh BD
    Urol Oncol; 2014 Jul; 32(5):707-13. PubMed ID: 24629494
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic significance of serum lactate dehydrogenase in patients with breast cancer: a meta-analysis.
    Liu D; Wang D; Wu C; Zhang L; Mei Q; Hu G; Long G; Sun W
    Cancer Manag Res; 2019; 11():3611-3619. PubMed ID: 31118783
    [No Abstract]   [Full Text] [Related]  

  • 58. Up-regulated serum lactate dehydrogenase could become a poor prognostic marker in patients with bladder cancer by an evidence-based analysis of 2,182 patients.
    Wei X; Chai Y; Li Z; Che X; Zhang Y; Zhou Z; Wang X
    Front Oncol; 2023; 13():1233620. PubMed ID: 37601656
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
    Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
    J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic significance of lactate dehydrogenase and its impact on the outcomes of gastric cancer: a systematic review and meta-analysis.
    Chen J; Zou X
    Front Oncol; 2023; 13():1247444. PubMed ID: 37727205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.